Author

Mukul Jain

President at Zydus Research Centre, Ahmedabad, India - Cited by 4,906 - Drug Discovery & Development

Biography

Mukul Jain currently works at Zydus Research Centre as President. Mukul does research in New Drug Discovery & Development area. He has expertise in Metabolic Diseases, Metabolic Endocrinology, Cardiovascular Risk, Diabetes Mellitus, Chronic Inflammation.   
Title
Cited by
Year
Role of mineralocorticoid receptor antagonists in kidney diseases
V Patel, A Joharapurkar, M JainDrug development research 82 (3), 341-363, 2021202
40
2021
Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
PD Yadav, S Kumar, K Agarwal, M Jain, DR Patil, K Maithal, B Mathapati, ...BioRxiv, 2021.02. 02.429480, 2021202
16
2021
ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
K Ghoshdastidar, H Patel, H Bhayani, A Patel, K Thakkar, D Patel, ...Pharmacology Research & Perspectives 8 (4), e00565, 2020202
10
2020
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor
S Agarwal, JP Pethani, HA Shah, V Vyas, S Sasane, H Bhavsar, ...Bioorganic & Medicinal Chemistry Letters 30 (21), 127571, 2020202
10
2020
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending …
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-148: a first-in-human, randomised, placebo-controlled, double-blind, single ascending …BE Barber, M Fernandez, HB Patel, C Barcelo, SD Woolley, H Patel, ...The Lancet Infectious Diseases 22 (6), 87-80, 2022202
9
2022
Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy
A Joharapurkar, V Patel, S Kshirsagar, MS Patel, H Savsani, M JainEuropean Journal of Pharmacology 899, 14032, 2021202
7
2021
Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress
AA Joharapurkar, VJ Patel, SG Kshirsagar, MS Patel, HH Savsani, ...Drug Development Research 82 (), 852-80, 2021202
6
2021
Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes
S Pola, SR Shah, H Pingali, P Zaware, B Thube, P Makadia, H Patel, ...Bioorganic & Medicinal Chemistry 3, 116071, 2021202
5
2021
Estradiol overcomes adiponectin-resistance in diabetic mice by regulating skeletal muscle adiponectin receptor 1 expression
S Chattopadhyay, A Joharapurkar, N Das, S Khatoon, S Kushwaha, ...Molecular and Cellular Endocrinology 40, 1112, 2022202
5
2022
ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection
PD Yadav, SK Mendiratta, S Mohandas, AK Singh, P Abraham, A Shete, ...Viruses 13 (12), 2424, 2021202
5
2021
Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β …
V Patel, A Joharapurkar, S Kshirsagar, M Patel, H Patel, H Savsani, ...Toxicology and Applied Pharmacology 3, 115825, 2022202
4
2022
Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B0AT1 (SLC6A19)
J Desai, B Patel, B Darji, A Gite, N Panchal, G Bhosale, S Shedage, ...Bioorganic & Medicinal Chemistry Letters 53, 12821, 2021202
4
2021
ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models
MR Jain, RB Patel, KD Prajapati, P Vyas, D Bandyopadhyay, V Prajapati, ...European Journal of Pharmacology 924, 174961, 2022202
3
2022
In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport
A Joharapurkar, S Kshirsagar, V Patel, M Patel, H Savsani, M JainBasic & Clinical Pharmacology & Toxicology 130 (1), 35-43, 0
2
2022
Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC–MS/MS, a novel antimalarial compound
Simultaneous estimation of ZY-19489 and its active metabolite ZY-0486 in human plasma using LC–MS/MS, a novel antimalarial compoundAM Ghoghari, HV Patel, NN Nayak, TH Mansuri, SM Pillai, MR Jain, ...Bioanalysis 13 (3), 1761-1777, 010
2
2021
Syntheses, biological evaluation of some novel substituted benzoic acid derivatives bearing hydrazone as linker
GP Mishra, R Sharma, M Jain, D BandyopadhyayResearch on Chemical Intermediates 47, 5061-5078, 010
2
2021
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
AA Joharapurkar, VJ Patel, SG Kshirsagar, MS Patel, HH Savsani, ...Current Research in Pharmacology and Drug Discovery 3, 10010, 0
2
2022
Hematological and biochemical reference intervals of wild-caught and inhouse adult Indian rhesus macaques (Macaca mulatta)
NA Shah, LK Bhatt, RJ Patel, TM Patel, NV Patel, HG Trivedi, NR Patel, ...Laboratory Animal Research 38 (1), 1-9, 0
2
2022
Needle‐free injection system delivery of ZyCoV‐D DNA vaccine demonstrated improved immunogenicity and protective efficacy in rhesus macaques against SARS‐CoV‐2
PD Yadav, S Kumar, K Agarwal, M Jain, DR Patil, K Maithal, B Mathapati, ...Journal of Medical Virology 95 (2), e28484, 2023202
1
2023
Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-Obese Mice
Combination of Lorcaserin and GLP-/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-Obese MiceV Patel, A Joharapurkar, S Kshirsagar, M Patel, H Savsani, R Bahekar, ...Drug Research 70 (08), 376-384, 2020202
1
2020

Referred From: https://scholar.google.com/citations?user=d5EbT8gAAAAJ

Cited by
Citations 4906
h-index 37
i10-index 121
Recommended Journals
Open Access Journals